Prostate Cancer (PCa) Biochip
Why use Biochip?
Over 50,000 men in the UK are diagnosed each year with Prostate Cancer (PCa), which is the second most common cancer in men. PCa costs for the NHS (UK) exceeded £320 million in 2020.
Gold standard PCa diagnosis is typically derived through histological assessment of prostate tissue obtained by Transperineal ultrasound-guided biopsy of the prostate (TURP). This method has however been associated with a 75% negative biopsy rate and the procedure also associated with increased rate of UTI (15.5%).
Randox have demonstrated novel serum combination of 4 biomarkers significantly improved the predictive potential of tPSA alone to identify patients with PCa.
The Evidence MultiSTAT
Meet the Evidence MultiSTAT
The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.
Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.
With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.
Meet the Cartridge
The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.
The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.
No other components are required.
